

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 2023;

SERIAL NUMBER FILING DATE		FIRST NAMED APPLICANT			ATTORNEY DOCKET NO	
07702079	700 03702767	USHIMA		1,-1-	5.1021	
2.77 Part		MARTIN & SCIMIC	7 [EXAMINER TOTA FIGURE PTC		
				ART UNIT	PAPER NUMBER	
	•			3.73	5	
			D	ATE MAILED:	097.16787	

541	his a	pplication has been examined Responsive to communication filed on	This action is made final.					
A she Failu	ortene ire to	ed statutory period for response to this action is set to expire	from the date of this letter. .S.C. 133					
Part I. 3. 5.	XX	THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION: Notice of References Cited by Examiner, PTO-892. Notice of Art Cited by Applicant, PTO-1449 Information on How to Effect Drawing Changes, PTO-1474 6.	tawing, PTO-948. Patent Application, Form PTO-152					
Part 1	l i	SUMMARY OF ACTION	•					
1.	×	\ \	are pending in the application. are withdrawn from consideration.					
2.		Claims	have been cancelled.					
3.		Claims are allowed.						
4.	X	Claims						
5.		Claims	are objected to.					
6.		Claims are subject to restriction or election requirement.						
1.		This application has been filed with informal drawings which are acceptable for examination purposes until such time as allowable subject matter is indicated.						
8.	[]	Allowable subject matter having been indicated, formal drawings are required in response to this Office action.						
9.		The corrected or substitute drawings have been received on These drawings are [] acceptable; not acceptable (see explanation).						
10.	U	The proposed drawing correction and/or the proposed additional or substitute sheet(s) of drawings, filed on has (have) been [] approved by the examiner. [] disapproved by the examiner (see explanation).						
11.		The proposed drawing correction, filed						
12.		Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has 🔀 been received 📋 not been received						
		been filed in parent application, serial no; filed on;						
13.	 Since this application appears to be in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under Exparte Quayle, 1935 C.D. 11; 453 O.G. 213. 							
14.		Other	J.					

Serial No. 034196

Art Unit 129

Receipt is acknowledged of papers submitted under 35 U.S.C. 119, which papers have been placed of record in the file.

This application contains claims directed to the following patentably distinct species of the claimed invention:

The species of the working examples.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 of the other invention.

Art Unit 129

Pursuant to the September 4, 1987 telephonic requirement for election of species, applicants' attorney, Mr. Perry, elected the compound No. 20. Claims 1 to 11 and 13 to 19 are grouped therewith. Claim 12 stands withdrawn form further consideration as not being readable on the elected species.

Claims 1 to 4, 18 and 19 are rejected as being improper Markush claims in the definition of X as =N-, =CH- and -CH₂-. So substituted, the resulting total compounds are structurally diverse and patentably distinct one from the other. A reference anticipating one under Section 102 would not be a reference against the others under Section 103. Limitation of the claims to compounds where X is =CH-, thus encompassing the elected species, will overcome this rejection.

Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

This claim is improperly dependent back on two previous claims.

The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit 129

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 1 to 11 and 13 to 19 are rejected under 35 U.S.C. 103 as being unpatentable over Tretter or Bloom et al in view of Rokach et al, Helsly et al, Takizawa et al and the Journal of Medicinal Chemistry articles. The primary references disclose 11-aminopropylidine substituted dibenzoxepines (useful as psychotherapeutic agents and as exhibiting antihistiminic activity). The secondary references disclose related dibenzoxepines substituted on the benzo ring with the various - Y-A substituents of the present compounds. Accordingly, the present substitution is held to be within the skill of the worker in the art.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the

Art Unit 129

obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103.

Applicants' citation of EP 214,779 is noted. Its publication is after the filing date of the present application.

RAYMOND: wdh

A/C 703 557-3920

9/15/87

CICHARD L. RAYMOND PRIMARY EXAMPLER ART UNIT 129